Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Blinatumomab’s place in the ALL treatment landscape

Ryan Cassaday • 20 Jun 2022
EHA 2022
Acute Lymphoblastic Leukemia Leukemia Antibodies Blinatumomab Dasatinib Ponatinib

Ryan Cassaday, MD, University of Washington, Seattle, WA, discusses blinatumomab’s place in the acute lymphoblastic leukemia (ALL) treatment landscape, highlighting its role in relapsed/refractory (R/R) disease, its future in the frontline setting, and the promise of combinations with other agents, including dasatinib and ponatinib. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Disclosures

Research funding from Amgen, Kite/Gilead, Merck, Pfizer, Servier, and Vanda Pharmaceuticals; consulting/honoraria from Amgen, Kite/Gilead, and Pfizer; and spouse is employed by and owns stock in Seagen.

More from Ryan Cassaday

2:39
The future of immunotherapy for the treatment of ALL
Ryan Cassaday • 20 Jun 2022
2:48
Results from a subgroup analysis of ZUMA-3 and the efficacy of brexu-cel in R/R B-ALL
Ryan Cassaday • 20 Jun 2022
3:01
Dose-adjusted EPOCH plus inotuzumab ozogamicin for B-ALL
Ryan Cassaday • 20 Jun 2022
2:31
Improving the SOC for ALL with inotuzumab
Ryan Cassaday • 1 Jun 2018

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals